Navigation Links
Popular Anemia Drug Dodges The Dagger

In a study that health professionals feel was long due, drug-manufacturing company Amgen concluded that its anaemia drug Aranesp does not increase the chances of death in// lung cancer patients who are undergoing chemotherapy. This has resulted in sales of the drug shooting up.

Aranesp, along with Epogen from Amgen and Procrit from Johnson & Johnson, are used by nearly a million Americans a year, mainly to treat anemia from kidney disease or cancer chemotherapy.

Last month, the Food and Drug Administration imposed strict new warnings on all three drugs after evidence emerged suggesting they could make cancer worse, cause heart problems or hasten death.

Amgen’s woes were deepened when drug maker Roche, ended a clinical trial with lung cancer patients that compared Aranesp with an anemia drug it was developing because of an unexpected number of deaths in at least some of the treatment groups. This suggested that the safety concerns of the drug were serious.

The clinical trial, which has put Amgen back on track, featured around 600 persons who were suffering from small cell lung cancer. It concluded that there was essentially no difference in survival between those who received Aranesp and those who received a placebo.

Although Roger M. Perlmutter, Amgen’s executive vice president for research and development, said in a statement that the results contributed to “reinforcing the neutral impact” of the anemia drugs on patients’ survival, Geoffrey C. Porges, an analyst at Sanford C. Bernstein & Company, said it was too early to assume that Amgen was out of the woods.

“If the study had been bad, it would have been an unmitigated disaster, but leaping to the conclusion that just because it’s O.K. in small-cell lung cancer, that makes it O.K. in head and neck cancer and breast cancer and colon cancer is ridiculous”, Porges was quoted.

According to Dr. John A. Glaspy, an oncologist at the University of California, Los Angeles, said the new results have gone a long way toward calming his concerns, although he agrees that it would be good to see similar results in one or two other types of cancer.

Yet Amgen’s troubles are not fading away yet. Representative Pete Stark, a California Democrat who heads the House Ways and Means Subcommittee on Health, sent a letter to his House colleagues yesterday urging a change in Medicare to remove incentives for dialysis centers to overuse the anemia drugs.

A recent study published in The Journal of the American Medical Association showed that profit-making dialysis centers used significantly more of the drugs than non-profit centers did.

Yet many experts in the medical field are wondering why it took Amgen such a long time to provide safety data for their drug. "We prescribe this drug to a million people a year and only now are we seriously examining if how we are treating them is harmful?" says Dr. Ajay K. Singh, professor of medicine at Harvard Medical School. "That's very disconcerting."

<
'"/>




Related medicine news :

1. Uterine Fibroid Embolization Gaining Popularity
2. Study Warns About The Use Of Popular Asthma Drug To Stop Childrens Coughs
3. Popularity Of Homeopathy On The Increase
4. Popularity Among Peers Increases Susceptibility To Smoking Habit Among School Children
5. Valentine Day Becoming Popular In India
6. Bio-functional Garments Gaining Popularity
7. Warfarin the Not So Popular Drug for Stroke
8. Tooth Enamel Eaten Away By Popular Drinks
9. Chinese NGO To Popularize Sex Education For Youngsters
10. Concerns About Popular Anti-Ulcer Pill Used For Inducing Labor
11. FDA issues warnings on Three Popular Asthma drug labels
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... New York, NY (PRWEB) , ... December 07, ... ... measurable amounts of the drug in their bodies, a researcher at the Icahn ... the journal Pediatric Research. , The study found that when young children are ...
(Date:12/7/2016)... LAKE CITY, UTAH (PRWEB) , ... December 07, ... ... productivity, today announced the release of Smart Device Remote Control through a new ... management across all platforms and strengthens its mobile solutions to help businesses maximize ...
(Date:12/7/2016)... ... December 07, 2016 , ... EnghouseSystems ... purchase price of approximately $17.4 million (net of the cash acquired), subject ... $13.2 million. Headquartered in Barcelona, Spain, Presence is a leading provider of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... It is vital ... is with useful, properly analyzed data. The team at Beckman Coulter has designed Kaluza, ... 'need for speed' and the need to operate in a GLP (Good Laboratory Practice) ...
(Date:12/7/2016)... ... December 07, 2016 , ... A quote from Dr. Edward Hallowell, ... on social media that offer a rare glimpse into the mind of those people ... New York Times bestselling author, has described people with ADHD as having “Ferrari engines ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... -- Research and Markets has announced the addition of ... Forecast to 2021" report to their offering. ... , , The immunohistochemistry ... at a CAGR of 7.3% during the forecast period of 2016 to ... and rapidly increasing geriatric population across the globe are the primary driving ...
(Date:12/7/2016)... , Dec. 7, 2016  Palatin Technologies, Inc. ... closed on a previously disclosed underwritten public offering ... Genuity acted as sole book-running manager, Roth Capital ... Markets acted as co-manager for the offering. ... million in net proceeds, allowing us to continue ...
Breaking Medicine Technology: